Sinor Soltanizadeh, Consultant in Gynaecological Oncological Team, shared a post on LinkedIn:
“Sometimes, scientific breakthroughs make you feel like we’re actually living in the future.
That was exactly how I felt watching the results of INTerpath-001 phase 3 study presented by the charismatic Australian Professor Georgina V. Long at the Presidential Symposium I at ESMO 2026.
The idea sounds almost like science fiction: take a patient’s cancer cells, use them to create a personalised vaccine, and train the body’s own immune system to recognise and attack the cancer. And the results? Promising!
There is still work to be done, and so far, this approach has been studied in patients with melanoma. But it got me wondering: Could personalised cancer vaccines become part of the future of gynaecological oncology?
And one final takeaway: if I ever get to present a study in the New England Journal of Medicine, remind me to invest in a good tailor and a presentation coach. Professor Long has set the bar pretty high.”
You can also read: INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma
